7 Optimising Prevention of Pneumococcal Disease with Pneumococcal Conjugate Vaccines Pfizer Symposium, 23 October 2010, 13:00-14:00

Abstract

Paediatricians play a critical role in the battle against pneumococcal diseases, with a front-line position in its ongoing surveillance and prevention. The addition of pneumococcal conjugate vaccines (PCVs) to the armamentarium has dramatically changed the landscape in this battle; PCV7 was introduced almost a decade ago, and has been shown to have had a strong impact on all pneumococcal diseases caused by vaccine serotypes.

This symposium will open by looking at the burden of invasive and non-invasive pneumococcal disease across Europe, comparing the incidence and prevalence pre- and post-PCV7, and examining the impact of the different vaccination schedules in force.

Putting all this into practice, a member of our distinguished faculty will present an interactive case study on paediatric empyema, giving the audience the chance to vote and share their views on treatment strategies for invasive pneumococcal diseases.

Finally, we will turn to consider the remaining burden of pneumococcal disease, looking at the broader coverage of the 13-valent PCV formulation, and the practicalities of transitioning from PCV7, as well as the opportunities for providing broader protection to already fully vaccinated children.

We very much hope you will join us for what promises to be a lively and educational event as we consider how best to optimise the prevention of pneumococcal diseases with PCVs.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD